Pages that link to "Q36781270"

The following pages link to Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins (Q36781270):

Displaying 48 items.

• Pathogenesis of human immunodeficiency virus infection (Q24634681) (← links)
• Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140 (Q30431941) (← links)
• Phage-displayed peptides having antigenic similarities with porcine epidemic diarrhea virus (PEDV) neutralizing epitopes (Q33256225) (← links)
• Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes (Q33783763) (← links)
• Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees (Q33898692) (← links)
• Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection (Q34119444) (← links)
• Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers (Q34151491) (← links)
• A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 (Q34306804) (← links)
• The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. (Q34306883) (← links)
• Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody (Q35170702) (← links)
• Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein (Q35665722) (← links)
• Identifying epitopes of HIV-1 that induce protective antibodies (Q35708836) (← links)
• Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59 (Q35763321) (← links)
• Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. (Q36366296) (← links)
• Antigenic conservation and immunogenicity of the HIV coreceptor binding site (Q36403587) (← links)
• The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design (Q36497712) (← links)
• Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum (Q36634341) (← links)
• Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization (Q36635390) (← links)
• B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins (Q36640639) (← links)
• Multivariate analysis of human immunodeficiency virus type 1 neutralization data (Q36808080) (← links)
• Peptides isolated from random peptide libraries on phage elicit a neutralizing anti-HIV-1 response: analysis of immunological mimicry (Q36844406) (← links)
• Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses (Q37084521) (← links)
• Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 (Q37596552) (← links)
• DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. (Q38877739) (← links)
• Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus (Q39577967) (← links)
• Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein (Q39875204) (← links)
• A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE. (Q39878801) (← links)
• Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein (Q40015450) (← links)
• Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques (Q40040768) (← links)
• Envelope Sequence Variation, Neutralizing Antibodies, and Primate Lentivirus Persistence (Q40393218) (← links)
• Synthetic peptides as diagnostic tools in virology. (Q40484822) (← links)
• Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. (Q40940339) (← links)
• Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles (Q40957591) (← links)
• A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice (Q41424896) (← links)
• Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization (Q41478638) (← links)
• Site-directed primary in vitro immunization: production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors. (Q41485730) (← links)
• Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies (Q43654259) (← links)
• Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog (Q44745703) (← links)
• HIV-1 binding and neutralizing antibodies of injecting drug users (Q45266508) (← links)
• Expression and immunological characterization of cardamom mosaic virus coat protein displaying HIV gp41 epitopes (Q45351263) (← links)
• The GPRLQPY motif located at the carboxy-terminal of the spike protein induces antibodies that neutralize Porcine epidemic diarrhea virus. (Q45398782) (← links)
• Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. (Q45874869) (← links)
• Immunoglobulin G abnormalities in HIV-1 infected individuals with lymphoma (Q47855338) (← links)
• Simple strategy to induce antibodies of distinct specificity: Application to the mapping of gp120 and inhibition of HIV-1 infectivity (Q62727136) (← links)
• Cellular and humoral antigenic epitopes in HIV and SIV (Q67899864) (← links)
• Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity (Q71678992) (← links)
• Multifaceted Consequences of Anti-gp41 Monoclonal Antibody 2F5 Binding to HIV Type 1 Virions (Q71783878) (← links)
• Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children (Q72814608) (← links)